Preliminary results from a clinical trial on an experimental Ebola vaccine developed by GlaxoSmithKline and the US National Institutes of Health suggest it is safe for use, researchers said Wednesday. The vaccine also generates an immune response to Ebola, said the early findings from the trial under way at Oxford University, and published in the New England Journal of Medicine. Its safety profile is pretty much as we had hoped," said Adrian Hill who led the trial at Oxford University. The vaccine does not contain infectious Ebola virus, so it cannot cause a person who is vaccinated to get sick from Ebola.
via Health News Headlines - Yahoo News http://ift.tt/1BqCGek
No comments:
Post a Comment